Drug Details
General Information of the Drug (ID: DR2569) | ||||
---|---|---|---|---|
Name |
Crizotinib
|
|||
Synonyms |
Crizotinib; 877399-52-5; Xalkori; PF-02341066; (R)-crizotinib; PF-2341066; PF 2341066; Crizotinib (PF-02341066); 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine; PF 02341066; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; UNII-53AH36668S; PF2341066; CHEMBL601719; Crizotinib (PF-2341066); CHEBI:64310; 877399-52-5 (free base); 53AH36668S; 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]PYRIDIN-2-AMINE; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine; 3-[(1r)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-Yl-1h-Pyrazol-4-Yl)pyridin-2-Amine; (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; Xalkori (TN); C21H22Cl2FN5O; Crizotinib [USAN:INN]; crizotinibum; VGH; PubChem19322; PF02341066; SCHEMBL93829; PF-2341066,Crizotinib; cc-190; Crizotinib (JAN/USAN/INN); PF-2341066(Crizotinib); GTPL4903; QCR-32; Crizotinib, >=98% (HPLC); PF-2341066 (Crizotinib); PF-2341066 - Crizotinib; AOB2688; EX-A096; SYN1139; PF-02341066 (Crizotinib); BCPP000116; DTXSID701009329; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; AMY10313; ABP000131; ANW-47749; BDBM50306682; MFCD12407409; NSC749005; NSC749769; NSC800080; ZINC35902489; AKOS015901233; AKOS015995207; CCG-264803; DB08865; GS-6178; NSC 756645; NSC-749005; NSC-749769; NSC-800080; PB11015; NCGC00250400-01; NCGC00250400-02; NCGC00250400-09; NCGC00250400-12; 2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-; HY-50878; AB0027203; BB 0261738; SW202555-3; W9013; D09731; Q-3209; 399P525; J-510370; Q5186964; BRD-K78431006-001-01-1; BRD-K78431006-001-03-7; 877399-52-5, 877399-53-6 (acetate); 3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-am ine; 3-(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy-5-1-(4-piperidinyl)-1H-pyrazol-4-yl-2-Pyridinamine; 3-[(R)-1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Lung cancer [ICD-11: 2C25] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C21H22Cl2FN5O
|
|||
PubChem CID | ||||
Canonical SMILES |
CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
|
|||
InChI |
1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
|
|||
InChIKey |
KTEIFNKAUNYNJU-GFCCVEGCSA-N
|
|||
CAS Number |
CAS 877399-52-5
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Norcantharidin | Epicauta pensylvanica | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | MET | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MHCC97-H | CVCL_4972 | Adult hepatocellular carcinoma | Homo sapiens | ||
Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
In-vivo Model | For a xenograft model, 2*106 human HepG2 cells were injected subcutaneously into the right flanks of the mice into the right flanks of the mice. | |||||
Experimental
Result(s) |
Cytotoxic autophagy resulting from inhibition of c-Met/mTOR signaling may be achieved in HCC by combined NCTD and crizotinib administration. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | ALK tyrosine kinase receptor (ALK) | Molecule Info | [3] | |
Proto-oncogene c-Met (MET) | Molecule Info | [3] | ||
Proto-oncogene c-Ros (ROS1) | Molecule Info | [3] | ||
KEGG Pathway | Ras signaling pathway | Click to Show/Hide | ||
2 | Rap1 signaling pathway | |||
3 | Cytokine-cytokine receptor interaction | |||
4 | Endocytosis | |||
5 | PI3K-Akt signaling pathway | |||
6 | Axon guidance | |||
7 | Focal adhesion | |||
8 | Adherens junction | |||
9 | Bacterial invasion of epithelial cells | |||
10 | Epithelial cell signaling in Helicobacter pylori infection | |||
11 | Malaria | |||
12 | Pathways in cancer | |||
13 | Transcriptional misregulation in cancer | |||
14 | Proteoglycans in cancer | |||
15 | MicroRNAs in cancer | |||
16 | Renal cell carcinoma | |||
17 | Melanoma | |||
18 | Central carbon metabolism in cancer | |||
19 | Non-small cell lung cancer | |||
Pathway Interaction Database | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | Click to Show/Hide | ||
2 | Arf6 signaling events | |||
3 | Signaling events mediated by TCPTP | |||
4 | Posttranslational regulation of adherens junction stability and dissassembly | |||
5 | Direct p53 effectors | |||
6 | Syndecan-1-mediated signaling events | |||
7 | Stabilization and expansion of the E-cadherin adherens junction | |||
8 | a6b1 and a6b4 Integrin signaling | |||
9 | FGF signaling pathway | |||
10 | Regulation of retinoblastoma protein | |||
Reactome | Sema4D mediated inhibition of cell attachment and migration | Click to Show/Hide | ||
WikiPathways | TGF beta Signaling Pathway | Click to Show/Hide | ||
2 | Signaling of Hepatocyte Growth Factor Receptor | |||
3 | Focal Adhesion | |||
4 | Extracellular vesicle-mediated signaling in recipient cells | |||
5 | Signaling Pathways in Glioblastoma | |||
6 | miR-targeted genes in squamous cell - TarBase | |||
7 | miR-targeted genes in muscle cell - TarBase | |||
8 | miR-targeted genes in lymphocytes - TarBase | |||
9 | miR-targeted genes in epithelium - TarBase | |||
10 | Semaphorin interactions | |||
11 | Spinal Cord Injury | |||
12 | Differentiation Pathway |